Page last updated: 2024-11-07

dipyrandium

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

dipyrandium: RN given is from CA online & refers to (3beta,17beta)-isomer; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID160228
MeSH IDM0046078

Synonyms (9)

Synonym
dipyrandium
1,1'-androstan-3beta,17beta-diylbis(1-methylpyrrolidinium)
unii-z4vbl3r6f9
pyrrolidinium, 1,1'-((3beta,5alpha,17beta)-androstane-3,17-diyl)bis(1-methyl-
89121-09-5
pyrrolidinium, 1,1'-((3.beta.,5.alpha.,17.beta.)-androstane-3,17-diyl)bis(1-methyl-
1-((3s,5s,8r,9s,10s,13s,14s,17s)-10,13-dimethyl-3-(1-methylpyrrolidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta(a)phenanthren-17-yl)-1-methylpyrrolidin-1-ium
1,1'-androstan-3.beta.,17.beta.-diylbis(1-methylpyrrolidinium)
Z4VBL3R6F9 ,
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]